NEWS AND EVENTS CADTH is hosting two Medical Devices and Drug Portfolio Information Sessions on Thursday, November 1, 2018, from 9:30 a.m. to 12:00 p.m. and from 1:30 p.m. to 4:00 p.m. EDT, respectively. Interested participants can attend in person, at 150 King Street West, Toronto, or via webinar. This annual event is an opportunity for all int...
NEWS & EVENTS CADTH was pleased to have announced the appointment of Mr. David Agnew, President of Seneca College, to Chair of the CADTH Board of Directors. Health Canada, CADTH, and INESSS are hosting a webinar September 26, 2018, from 10:00 AM to 12:00 PM EDT to provide details on the aligned review process that was announced in June 2018....
NEWS CDR Update 137 / pCODR Update 67: Highlights the new aligned drug reviews from Health Canada, CADTH (through our Common Drug Review and pan-Canadian Oncology Drug Review programs), and the Institut national d’excellence en santé et en services sociaux (INESSS), which will help reduce the time between market authorization and drug reimburse...
DRUG REIMBURSEMENT RECOMMENDATIONS CADTH Common Drug Review CDR Update — Issue 136: Highlights in this issue include details about the updated CADTH Canadian Drug Expert Committee meeting schedule, an updated Advance Notification Form, an update on drug plan participation in pre-submission meetings, and details about pending changes to the Key M...
DRUG REIMBURSEMENT RECOMMENDATIONS CADTH Common Drug Review Ocrelizumab (Ocrevus): Primary progressive multiple sclerosis Nitisinone (MDK-Nitisinone): Hereditary tyrosinemia type I Latanoprost (Monoprost): Glaucoma and ocular hypertension CADTH pan-Canadian Oncology Drug Review (pCODR) Alectinib (Alecensaro): Locally advanced or metastatic non‒s...
DRUG REIMBURSEMENT RECOMMENDATIONS CADTH Common Drug Review (CDR) Tocilizumab (Actemra): Giant cell arteritis (GCA) Tenofovir alafenamide (Vemlidy): Hepatitis B, chronic CDR Update 135: Application Fees for CADTH Pharmaceutical Reviews — Adjustment CADTH pan-Canadian Oncology Drug Review (pCODR) Pembrolizumab (Keytruda): Metastatic Urothelial Ca...
DRUG REIMBURSEMENT RECOMMENDATIONS CADTH Common Drug Review Nitisinone (Orfadin): Hereditary tyrosinemia type 1 Guselkumab (Tremfya): Psoriasis, moderate-to-severe plaque Infliximab (Renflexis): rheumatoid arthritis, ankylosing spondylitis, adult Crohn’s disease, pediatric Crohn’s disease, fistulising Crohn’s disease, adult ulcerative colitis, p...
DRUG REIMBURSEMENT RECOMMENDATIONS CADTH Common Drug Review Migalastat (Galafold): Fabry Disease Cysteamine bitartrate (Procysbi): Nephropathic cystinosis Glecaprevir pibrentasvir (Maviret): Chronic Hepatitis C Apomorphine hydrochloride (Movapo): Parkinson's disease Sofosbuvir velpatasvir voxilaprevir (Vosevi): Chronic Hepatitis C CADTH pan-Cana...
DRUG REIMBURSEMENT RECOMMENDATIONS CADTH Common Drug Review Read the following CDR Update to find out what’s happening in CDR: Issue 132 — Update on Revised Process for Biosimilars, and Clarification Regarding Eligibility Assessments for Resubmissions. Nusinersen (Spinraza): Spinal Muscular Atrophy CADTH pan-Canadian Oncology Drug Review (pCODR)...
DRUG REIMBURSEMENT RECOMMENDATIONS CADTH Common Drug Review Read the following CDR Update to find out what’s happening in CDR: Issue 130 — Revised Procedure for the CADTH Common Drug Review Resubmissions, Industry Fees are Applicable to all CDR Resubmissions, and Revised Table of Studies Template. Issue 131 — Collaborative Workspaces: Revised Pr...